Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

ABEO

Live52w high -24.3%

Annual Quarterly

Core line items from ABEO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: ABEONA THERAPEUTICS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$13.57M	$8.72M	$5.82M	$400.00K	$400.00K
Operating Income	Not available	$-23.03M	$-89.45M	$-66.54M	$-42.52M
Net Income	Not available	$-17.07M	$71.18M	$91.64M	$96.80M
EPS (Diluted)	$-0.24	$-0.30	$1.01	$1.35	$1.47
Total Assets	Not available	$198.49M	$219.57M	$231.09M	$246.23M
Total Liabilities	Not available	$53.55M	$60.35M	$59.86M	$82.66M
Cash & Equivalents	Not available	$61.37M	$78.44M	$82.88M	$163.53M
Free Cash Flow OCF − CapEx	Not available	$-20.74M	$-84.30M	$-65.19M	$-41.49M
Shares Outstanding	Not available	56.87M	55.04M	52.40M	51.25M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from ABEO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -24.3%

Entity: ABEONA THERAPEUTICS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$13.57M	$8.72M	$5.82M	$400.00K	$400.00K
Operating Income	Not available	$-23.03M	$-89.45M	$-66.54M	$-42.52M
Net Income	Not available	$-17.07M	$71.18M	$91.64M	$96.80M
EPS (Diluted)	$-0.24	$-0.30	$1.01	$1.35	$1.47
Total Assets	Not available	$198.49M	$219.57M	$231.09M	$246.23M
Total Liabilities	Not available	$53.55M	$60.35M	$59.86M	$82.66M
Cash & Equivalents	Not available	$61.37M	$78.44M	$82.88M	$163.53M
Free Cash Flow OCF − CapEx	Not available	$-20.74M	$-84.30M	$-65.19M	$-41.49M
Shares Outstanding	Not available	56.87M	55.04M	52.40M	51.25M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.